deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT00115739

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma

Phase II Trial Evaluating Gleevec (Imatinib Mesylate Formerly Known as STI571) in Patients With Anaplastic Thyroid Cancer

Sponsor: University of Michigan Rogel Cancer Center

Conditions Thyroid Cancer
Interventions Imatinib
Updated 8 times since 2017 Last updated: Mar 19, 2014 Started: Feb 29, 2004 Primary completion: May 31, 2008 Completion: Aug 31, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study was closed early due to slow accrual

Other terminated trials from University of Michigan Rogel Cancer Center

See all terminations from University of Michigan Rogel Cancer Center

Other Thyroid Cancer trials with similar outcome

Browse all Thyroid Cancer trials

Listed as NCT00115739, this PHASE2 trial focuses on Thyroid Cancer and remains terminated or withdrawn. Sponsored by University of Michigan Rogel Cancer Center, it has been updated 8 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshotTerminated~Feb 2019 – ~Jan 2021 · 23 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 21 months · monthly snapshotTerminated

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  5. Feb 2019 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 3 earlier versions

  1. Jun 2018 — Feb 2019 [monthly]

    Terminated PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Michigan Rogel Cancer Center
Data source: University of Michigan Rogel Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations